Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Arcutis Biotherapeutics, Inc. (ARQT : NSDQ)
 
 • Company Description   
Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis, atopic dermatitis, seborrheic dermatitis and eczema, which are in clinical stage. Arcutis Biotherapeutics Inc. is based in Westlake Village, California.

Number of Employees: 147

 
 • Price / Volume Information   
Yesterday's Closing Price: $18.25 Daily Weekly Monthly
20 Day Moving Average: 246,378 shares
Shares Outstanding: 51.42 (millions)
Market Capitalization: $938.38 (millions)
Beta: 0.28
52 Week High: $29.37
52 Week Low: $13.59
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -9.20% -0.51%
12 Week 14.20% 23.92%
Year To Date -12.01% 4.64%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2945 TOWNSGATE ROAD SUITE 110
-
WESTLAKE VILLAGE,CA 91361
USA
ph: 805-418-5006
fax: -
ir@arcutis.com http://www.arcutis.com
 
 • General Corporate Information   
Officers
Todd Franklin Watanabe - President; Chief Executive Officer and Director
Patrick J. Heron - Chairman and Director
Scott L. Burrows - Chief Financial Officer
Bhaskar Chaudhuri - Director
Terrie Curran - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 03969K108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 51.42
Most Recent Split Date: (:1)
Beta: 0.28
Market Capitalization: $938.38 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.36 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-5.74 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.08
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -67.11%
vs. Previous Quarter: 10.56%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -65.47
12/31/21 - -54.08
09/30/21 - -45.12
ROA
03/31/22 - -57.32
12/31/21 - -48.57
09/30/21 - -42.55
Current Ratio
03/31/22 - -
12/31/21 - 12.09
09/30/21 - 20.03
Quick Ratio
03/31/22 - -
12/31/21 - 12.09
09/30/21 - 20.03
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - 5.92
09/30/21 - 7.22
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.24
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - -
12/31/21 - 19.55
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©